

Marina A Pereira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5681245/publications.pdf>

Version: 2024-02-01

64
papers

680
citations

567281

15
h-index

642732

23
g-index

68
all docs

68
docs citations

68
times ranked

812
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Role of Neutrophil/Lymphocyte Ratio in Resected Gastric Cancer: A Systematic Review and Meta-analysis. <i>Clinics</i> , 2018, 73, e360.	1.5	59
2	Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 829-839.	1.7	57
3	Surgical treatment of gastric cancer: a 10-year experience in a high-volume university hospital. <i>Clinics</i> , 2018, 73, e543s.	1.5	35
4	Carnoy's solution increases the number of examined lymph nodes following gastrectomy for adenocarcinoma: a randomized trial. <i>Gastric Cancer</i> , 2016, 19, 136-142.	5.3	34
5	Carnoy's solution is an adequate tissue fixative for routine surgical pathology, preserving cell morphology and molecular integrity. <i>Histopathology</i> , 2015, 66, 388-397.	2.9	29
6	Risk Factors for Lymph Node Metastasis in Western Early Gastric Cancer After Optimal Surgical Treatment. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 23-31.	1.7	27
7	Duodenal fistula: The most lethal surgical complication in a case series of radical gastrectomy. <i>International Journal of Surgery</i> , 2018, 53, 366-370.	2.7	26
8	Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype?. <i>Journal of Surgical Oncology</i> , 2019, 121, 804-813.	1.7	25
9	Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer. <i>Journal of Surgical Oncology</i> , 2018, 117, 851-857.	1.7	24
10	Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer. <i>Journal of Surgical Oncology</i> , 2020, 121, 795-803.	1.7	24
11	Surgical outcomes of gastrectomy with D1 lymph node dissection performed for patients with unfavorable clinical conditions. <i>European Journal of Surgical Oncology</i> , 2019, 45, 460-465.	1.0	22
12	DETECTION OF OCCULT LYMPH NODE TUMOR CELLS IN NODE-NEGATIVE GASTRIC CANCER PATIENTS. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2017, 30, 30-34.	0.5	18
13	Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 761-771.	3.8	18
14	CONVERSION THERAPY FOR GASTRIC CANCER: EXPANDING THE TREATMENT POSSIBILITIES. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2019, 32, e1435.	0.5	18
15	Impact of neoadjuvant chemotherapy on surgical and pathological results of gastric cancer patients: A case-control study. <i>Journal of Surgical Oncology</i> , 2020, 121, 833-839.	1.7	18
16	Lymph Node Yield After Neoadjuvant Chemoradiotherapy in Rectal Cancer Specimens: A Randomized Trial Comparing Two Fixatives. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 888-896.	1.3	17
17	Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 19-27.	1.7	17
18	Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 526-536.	2.2	17

#	ARTICLE	IF	CITATIONS
19	Lymphoepithelioma-like gastric carcinoma: clinicopathological characteristics and infection status. <i>Journal of Surgical Research</i> , 2017, 210, 159-168.	1.6	16
20	Esophagojejunal anastomotic fistula: a major issue after radical total gastrectomy. <i>Updates in Surgery</i> , 2019, 71, 429-438.	2.0	12
21	Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1039-1048.	2.8	12
22	Multivisceral resection vs standard gastrectomy for gastric adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 840-847.	1.7	12
23	Gastric partitioning for the treatment of malignant gastric outlet obstruction. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 1161-1171.	2.0	12
24	Cytotoxic T lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression. <i>Journal of Surgical Oncology</i> , 2021, 124, 1040-1050.	1.7	9
25	Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: Analysis in western patients after curative-intent surgery. <i>World Journal of Clinical Oncology</i> , 2021, 12, 688-701.	2.3	9
26	Surgical results of remnant gastric cancer treatment. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2020, 47, e20202703.	0.6	9
27	Prediction scores for complication and recurrence after multivisceral resection in gastric cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1097-1102.	1.0	8
28	Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy. <i>Journal of Surgical Research</i> , 2021, 261, 130-138.	1.6	7
29	Laparoscopic gastrectomy for early and advanced gastric cancer in a western center: a propensity score-matched analysis. <i>Updates in Surgery</i> , 2021, 73, 1867-1877.	2.0	7
30	Impact of COVID-19 pandemic on the surgical treatment of gastric cancer. <i>Clinics</i> , 2021, 76, e3508.	1.5	7
31	Remnant gastric cancer: a neglected group with high potential for immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3373-3383.	2.5	6
32	Gastric Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Western Center Case Series. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 47.	2.9	5
33	Neutrophil-lymphocyte ratio change after curative gastrectomy for gastric cancer: a subgroup analysis. <i>Einstein (Sao Paulo, Brazil)</i> , 2019, 18, eAO4860.	0.7	5
34	Laparoscopic D2 Gastrectomy for Gastric Cancer: Mid-Term Results and Current Evidence. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2019, 29, 495-502.	1.0	4
35	GASTRECTOMY IN OCTOGENARIANS WITH GASTRIC CANCER: IS IT FEASIBLE?. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2020, 33, e1552.	0.5	4
36	Searching for SARS-CoV-2 in Cancer Tissues: Results of an Extensive Methodologic Approach based on ACE2 and Furin Expression. <i>Cancers</i> , 2022, 14, 2582.	3.7	4

#	ARTICLE	IF	CITATIONS
37	SURGICAL TREATMENT IN CLINICAL STAGE IV GASTRIC CANCER: A COMPARISON OF DIFFERENT PROCEDURES AND SURVIVAL OUTCOMES. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 0, 35, .	0.5	4
38	Tumor size predicts worse prognosis in esophagogastric junction adenocarcinoma. Updates in Surgery, 2022, 74, 1871-1879.	2.0	4
39	One-level step section histological analysis is insufficient to confirm complete pathological response after neoadjuvant chemoradiation for rectal cancer. Techniques in Coloproctology, 2017, 21, 745-754.	1.8	3
40	RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients. Medical Sciences (Basel, Switzerland), 2022, 10, 4.	2.9	3
41	Predictive factors of recurrence in adenocarcinoma of the esophagogastric junction in the multimodal era. American Journal of Surgery, 2021, 221, 631-636.	1.8	2
42	Remnant gastric cancer: An ordinary primary adenocarcinoma or a tumor with its own pattern?. World Journal of Gastrointestinal Surgery, 2021, 13, 366-378.	1.5	2
43	Predictors of pathological response and tumor regression following neoadjuvant therapy in advanced gastric cancer patients.. Journal of Clinical Oncology, 2017, 35, 206-206.	1.6	2
44	CARNOYâ€™S SOLUTION INCREASES LYMPH NODES COUNT IN COLON CANCER SPECIMENS WHEN COMPARED TO FORMALIN FIXATION: A RANDOMIZED TRIAL. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 0, 35, .	0.5	2
45	Biochemical and molecular characterization of thyroid tissue by micro-Raman spectroscopy and gene expression analysis. Proceedings of SPIE, 2016, , .	0.8	1
46	Reply to: "Association between neutrophil-lymphocyte ratio and prognosis after potentially curative resection for gastric cancer". Journal of Surgical Oncology, 2018, 117, 1855-1855.	1.7	1
47	560 "The Impact of Postoperative Complications on a Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients. Gastroenterology, 2019, 156, S-1402-S-1403.	1.3	1
48	Schistosomiasis Misleading Gastric Cancer Treatment. Journal of Gastrointestinal Cancer, 2020, 51, 643-646.	1.3	1
49	Gastric Remnant Carcinosarcoma: Case Report and Review of the Literature. Journal of Gastrointestinal Cancer, 2021, 52, 336-341.	1.3	1
50	Locally Advanced Gastric Adenocarcinoma with Impressive Response to Hemostatic Radiation: the Possible Role of p53 Status and Eosinophilic Infiltrate. Journal of Gastrointestinal Cancer, 2021, 52, 788-791.	1.3	1
51	RECURRENCE IN PNO GASTRIC CANCER: RISK FACTORS IN THE OCCIDENT. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2021, 34, e1562.	0.5	1
52	IMPACT OF AGING IN THE SURGICAL OUTCOMES OF GASTRIC CANCER PATIENTS. Arquivos De Gastroenterologia, 2021, 58, 93-99.	0.8	1
53	Expression profiles of gastric cancer molecular subtypes in remnant tumors. World Journal of Gastrointestinal Oncology, 2021, 13, 265-278.	2.0	1
54	Impact of adjuvant treatment according to gastric cancer molecular subtypes.. Journal of Clinical Oncology, 2019, 37, e15513-e15513.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Epstein-Barr Virus and PD-L1 in Esophageal and Esophagogastric Junction Cancer: Differences According to Location and Histological Type. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 2358-2364.	1.7	1
56	Sa1222 VALIDATION OF EXPANDED ENDOSCOPIC SUBMUCOSAL DISSECTION CRITERIA FOR TREATMENT OF EARLY GASTRIC ADENOCARCINOMA IN A WESTERN CENTER. <i>Gastrointestinal Endoscopy</i> , 2018, 87, AB170-AB171.	1.0	0
57	Immunohistochemical Scores for Programmed Death Ligand-1 (PD-L1) Expression and Prognostic in Patients with Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 231, e208.	0.5	0
58	Remnant Gastric Cancer: Neglect Group with High Potential for Immunotherapy. <i>Journal of the American College of Surgeons</i> , 2020, 231, e212.	0.5	0
59	Jejunostomy in the palliative treatment of gastric cancer: A clinical prognostic score. <i>World Journal of Clinical Oncology</i> , 2021, 12, 935-946.	2.3	0
60	Prospective results of perioperative chemotherapy (PCT) with cisplatin and irinotecan for locally advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 147-147.	1.6	0
61	Clinicopathological Characteristics and Prognostic Value of Epstein-Barr Virus-associated Gastric Cancer, Microsatellite Instability and PD-L1 Immunoexpression. <i>American Journal of Gastroenterology</i> , 2017, 112, S665-S667.	0.4	0
62	PD-L1 Expression in Gastric Cancer: Correlation Between the Primary Site and Metastatic Lymph Node. <i>Journal of the American College of Surgeons</i> , 2021, 233, S251-S252.	0.5	0
63	Common variable immunodeficiency: an important but little-known risk factor for gastric cancer. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2021, 48, e20213133.	0.6	0
64	Gastric cancer with concurrent pancreatic schwannoma: A case report. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2022, 13, 107-113.	1.0	0